Cynthia L. Palmer

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Qinhua Huang, Ted W. Johnson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 118 citations · Full text

Medicine, Oncology, Pharmacology +14

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Cynthia L. Palmer, Britton Boras, Bernadette Pascual et al. · Cancer Cell · 2025 · 51 citations · Full text

Medicine, Oncology, Pharmacology +13

Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis

Mark Nuijten, Peter van Iperen, Cynthia L. Palmer et al. · Value in Health · 2001 · 37 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacology +14

Best Practice Implementation: Lessons Learned from 20 Partnerships

Paul J. Sharek, Charlotte Mullican, Angela Lavanderos et al. · The Joint Commission Journal on Quality and Patient Safety · 2007 · 21 citations

Public Health, Health Services Administration, Health Systems +12